DuPont de Nemours, Inc. (DD) SEC Filings & Earnings Calls
EquiReason read 18 DuPont de Nemours, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-09-10 — DuPont, Chemours and Corteva entered into a $455M settlement with North Carolina over PFAS contamination from Fayetteville Works facility. DuPont recorded a $125M probable loss in .
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 18.4B
- P/E TTM
- —
- Dividend yield
- 1.8%
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
10 Sep 20268-K · 1.01, 7.01DuPont, Chemours and Corteva entered into a $455M settlement with North Carolina over PFAS contamination from Fayetteville Works facility. DuPont recorded a $125M probable loss in Q2 2026. Settlement resolves all claims related to PFAS emisopen
Figures in the filing · each found in the filing text
| Settlement payment · 2026 | $455M | |
| Probable loss recorded · Q2-2026 | $125M | |
| Reserve fund · 2026 | $135M |
Risks flagged
Ongoing PFAS litigation and regulatory exposure
“the outcome of any pending or future litigation related to PFAS, including personal injury claims and natural resource damages claims; the extent and cost of ongoing remediation obligations and potential future remediation obligations; changes in laws and regulations applicable to PFAS chemicals” · word for word
4 Aug 20268-K · 2.02DuPont reports Q2 2026 net sales $1.819B (+4% YoY), operating EBITDA $448M (+6%), adjusted EPS $1.88 (+48%), raises full-year guidance for net sales, operating EBITDA, and adjusted EPS.earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q2-2026 | $1.82B | +4% y/y |
| Operating EBITDA · Q2-2026 | $448M | +6% y/y |
| Operating EBITDA margin · Q2-2026 | 24.6% | |
| GAAP EPS from continuing operations · Q2-2026 | $1.37 | +706% y/y |
| Adjusted EPS · Q2-2026 | $1.88 | +48% y/y |
| Cash provided by operating activities – cont. ops. · Q2-2026 | $400M | +441% y/y |
| Transaction-adjusted free cash flow · Q2-2026 | $326M | +205% y/y |
| GAAP Income from continuing operations · Q2-2026 | $191M | +696% y/y |
Guidance
FY26 net sales raised to $7.16-7.19B; operating EBITDA raised to $1.75-1.77B; adjusted EPS raised to $7.17-7.32; organic sales growth expected slightly above 4%
Raised full-year guidance across all key metrics after Q2 beat; mid-single-digit organic growth expected in H2.
Risks flagged
Healthcare & Water Technologies margin contraction of 30 bps due to mix and growth investments.
“Operating EBITDA margin 30.1% vs 30.4% YoY”
Weakness in Middle East water markets partially offset growth.
“Water Technologies sales up low-single digits, partially offset by weakness in the Middle East”
4 Aug 202610-QDuPont reported Q2 2026 results with 4% organic sales growth, improved segment profitability, strong cash flow, and active share buybacks, but also initiated a restructuring program.earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q2-2026 | $1.82B | +4% y/y |
| Operating cash flow from continuing operations · H1-2026 | $632M | +319% y/y |
| Operating EBITDA - Healthcare & Water Technologies · Healthcare & Water Technologies · Q2-2026 | $258M | +4% y/y |
| Operating EBITDA - Diversified Industrials · Diversified Industrials · Q2-2026 | $213M | +7% y/y |
| Total debt · 2026-06-30 | $3.13B |
Risks flagged
Tariff uncertainty
“the ruling remains subject to further appeal by the U.S. government... the ultimate outcome of which could affect future results.” · word for word
Restructuring execution risk
“Anticipated pre-tax restructuring charges and asset related charges and other cost savings of approximately $100 million to $150 million” · word for word
PFAS litigation liability
“DuPont together with Chemours and Corteva agreed to a proposed Judicial Consent Order with the State of New Jersey... DuPont's initial payment will be due within 30 days of the entry of the JCO.” · word for word
5 May 20268-K · 2.02Net Sales $1.68B (+4% y/y); GAAP Income from Continuing Operations $150M (+88% y/y); Operating EBITDA $414M (+15% y/y); Guidance: FY26 net sales $7,155-$7,215M, operating EBITDA $1,730-$1,760M, adjusted EPS $2.35-$2.40earningsopen
Figures in the filing · each found in the filing text
| Net Sales · Q1-2026 | $1.68B | +4% y/y |
| GAAP Income from Continuing Operations · Q1-2026 | $150M | +88% y/y |
| Operating EBITDA · Q1-2026 | $414M | +15% y/y |
| Operating EBITDA Margin · Q1-2026 | 24.6% | |
| GAAP EPS from Continuing Operations · Q1-2026 | $0.36 | +89% y/y |
| Adjusted EPS · Q1-2026 | $0.55 | +53% y/y |
| Cash Provided by Operating Activities - Cont. Ops · Q1-2026 | $232M | +201% y/y |
| Transaction-Adjusted Free Cash Flow · Q1-2026 | $147M | |
| Healthcare & Water Technologies Net Sales · Healthcare & Water Technologies · Q1-2026 | $806M | +6% y/y |
| Healthcare & Water Technologies Operating EBITDA · Healthcare & Water Technologies · Q1-2026 | $244M | +9% y/y |
Guidance
FY26 net sales $7,155-$7,215M, operating EBITDA $1,730-$1,760M, adjusted EPS $2.35-$2.40
DuPont raised full-year 2026 guidance due to strong Q1 performance and interest income benefit from Aramids divestiture, with organic growth expected to be about 4%.
Risks flagged
Logistics disruptions in the Middle East impacting Water Technologies sales.
“Water Technologies sales down low to mid-single digits on organic basis as strength in industrial water and microelectronics markets were more than offset by logistics disruptions in the Middle East.” · word for word
Ongoing weakness in construction markets affecting Building Technologies.
“Building Technologies sales down low-single digits on organic basis from ongoing weakness in construction markets.” · word for word
5 May 202610-QNet sales $1.68B (+4% y/y); Cost of sales as % of net sales 64; Healthcare & Water Technologies Net sales $806M (+6% y/y)open
Figures in the filing · each found in the filing text
| Net sales · Q1-2026 | $1.68B | +4% y/y |
| Cost of sales as % of net sales · Q1-2026 | 64.0% | |
| Healthcare & Water Technologies Net sales · Healthcare & Water Technologies · Q1-2026 | $806M | +6% y/y |
| Healthcare & Water Technologies Operating EBITDA · Healthcare & Water Technologies · Q1-2026 | $244M | +9% y/y |
| Diversified Industrials Net sales · Diversified Industrials · Q1-2026 | $875M | +3% y/y |
| Diversified Industrials Operating EBITDA · Diversified Industrials · Q1-2026 | $200M | +8% y/y |
| Operating cash flow · Q1-2026 | $232M | +201% y/y |
Risks flagged
Tariff refund uncertainty
“timing, scope, and mechanics of any refunds remain uncertain and dependent on future legal outcomes” · word for word
Middle East logistics disruption
“Organic sales declines in Water Technologies were driven by logistics disruptions in the Middle East” · word for word
Construction market weakness
“Building Technologies decline in organic sales was due to ongoing weakness in construction markets” · word for word
15 Apr 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open
Risks flagged
Loss of experienced director; minimal as departure is amicable and for external CEO role
“resignation in connection with his future appointment as Chief Executive Officer of Corteva, Inc.”
10 Apr 2026DEF 14ADuPont filed its definitive proxy statement (DEF 14A) for the 2026 annual meeting of stockholders.open
Figures in the filing · each found in the filing text
| Net Sales · FY2025 | $6.80B | |
| GAAP income from continuing operations · FY2025 | $98M | |
| Operating EBITDA · FY2025 | $1.63B | |
| GAAP EPS from continuing operations · FY2025 | $0.21 | |
| Adjusted EPS · FY2025 | $1.68 |
18 Mar 20268-K · 8.01DuPont announced plans to seek shareholder approval for a reverse stock split at a ratio between 1-for-2 and 1-for-4, to be determined by the Board.open
Risks flagged
Reverse stock split may indicate low stock price; no fundamental change
“Reverse stock split proposal; no other material events.”
16 Mar 20268-K · 7.01DuPont announces expected close of aramids business sale to Arclin on April 1, 2026; all regulatory conditions satisfied as of March 10, 2026.open
Risks flagged
Transaction completion risk; forward-looking statements caution about potential delays or failure to close.
“Forward-looking statements caution that actual results may differ materially due to risks including failure to satisfy conditions, unforeseen liabilities, and other factors.”
17 Feb 202610-KNet sales - Healthcare & Water Technologies $3.23B (+9% y/y); Operating EBITDA - Healthcare & Water Technologies $972M (+15% y/y); Net sales - Diversified Industrials $3.62B (-3% y/y); Guidance: 2026E capex ~$320M; Healthcare continued growopen
Figures in the filing · each found in the filing text
| Net sales - Healthcare & Water Technologies · Healthcare & Water Technologies · FY2025 | $3.23B | +9% y/y |
| Operating EBITDA - Healthcare & Water Technologies · Healthcare & Water Technologies · FY2025 | $972M | +15% y/y |
| Net sales - Diversified Industrials · Diversified Industrials · FY2025 | $3.62B | -3% y/y |
| Operating EBITDA - Diversified Industrials · Diversified Industrials · FY2025 | $800M | -5% y/y |
| Capital expenditures · FY2025 | $333M | +17% y/y |
| Cash and cash equivalents · 2025-12-31 | $715M | -60% y/y |
| Total debt · 2025-12-31 | $3.19B | -56% y/y |
| Cash provided by operating activities - continuing operations · FY2025 | $560M | -27% y/y |
| Dividends paid per common share · FY2025 | $1.43 | -6% y/y |
Guidance
2026E capex ~$320M; Healthcare continued growth; Water continued growth; Building Technologies flat; Industrial Technologies low-single digit growth
2026 outlook: Healthcare and Water segments expected to grow, Building Technologies flat, Industrial Technologies low-single digit growth. Capex expected to be about $320M, similar to 2025 levels.
Risks flagged
China antitrust investigation
“SAMR has suspended the antitrust investigation process. DuPont Tyvek ® sales to China in full year 2025 were approximately 1 percent of DuPont’s 2025 consolidated net sales.” · word for word
Tariff exposure
“Any modification of existing tariffs, or the introduction of new U.S. tariffs under alternative authorities, on imports from the countries where we do business for an extended period and without specific exemptions for our products, and any reciprocal tariffs or other reactions by other countries thereto, could have a material adverse impact on our financial”
Tax holiday expiration
“Our manufacturing facilities in Costa Rica operate under the Free Trade Zone regime, and we also benefit from tax holidays and tax incentive grants in various other countries. Unless these incentives and grants are extended, they will expire between 2028 and 2034.”
10 Feb 20268-K · 2.02Net sales $1.69B (+0% y/y); Operating EBITDA $409M (+4% y/y); GAAP EPS from continuing operations $-0.27; Guidance: Initiated Q1 and FY2026 guidance; exceeded Q4 and FY2025 guidanceearningsopen
Figures in the filing · each found in the filing text
| Net sales · Q4-2025 | $1.69B | 0% y/y |
| Operating EBITDA · Q4-2025 | $409M | +4% y/y |
| GAAP EPS from continuing operations · Q4-2025 | $-0.27 | |
| Adjusted EPS · Q4-2025 | $0.46 | +18% y/y |
| Transaction-adjusted free cash flow · Q4-2025 | $228M | +92% y/y |
| Full Year Net sales · FY2025 | $6.80B | +2% y/y |
| Full Year Operating EBITDA · FY2025 | $1.63B | |
| Full Year GAAP EPS from continuing operations · FY2025 | $0.21 | |
| Full Year Adjusted EPS · FY2025 | $1.68 | |
| Full Year Transaction-adjusted free cash flow · FY2025 | $689M |
Guidance
Initiated Q1 and FY2026 guidance; exceeded Q4 and FY2025 guidance
DuPont exceeded Q4 and full year 2025 guidance and initiated Q1 and FY2026 guidance, indicating confidence in continued momentum.
Risks flagged
Weakness in construction and printing/packaging markets impacting Diversified Industrials segment.
“Building Technologies sales down high-single digits on an organic basis from ongoing weakness in construction markets; Industrial Technologies sales down low-single digits due to weakness in printing and packaging markets.” · word for word
Separation-related costs and payments impacting reported cash flow.
“Cash provided by operating activities from continuing operations of $87 million included $228 million of separation-related transaction cost and other payments.” · word for word
4 Dec 20258-K · 8.01Minimum ebitda $1.40Bopen
Figures in the filing · each found in the filing text
| minimum_ebitda · point_in_time | $1.40B |
19 Nov 20258-K · 1.01, 2.03, 8.01Tendered notes principal $739Mopen
Figures in the filing · each found in the filing text
| tendered_notes_principal · Q4-2025 | $739M |
Risks flagged
Debt tender reduces outstanding leverage but may indicate refinancing or balance sheet optimization.
“tender offer to purchase for cash up to an aggregate principal amount of $739,256,000 of the 2048 Notes” · word for word
6 Nov 20258-K · 2.02Operating ebitda $840M (+6% y/y); gaap income from continuing operations $308M (-32% y/y); gaap eps from continuing operations $0.70 (-34% y/y); Guidance: FY 2025 operating EBITDA guidance raised to $1.6Bearningsopen
Figures in the filing · each found in the filing text
| operating_ebitda · Q3-2025 | $840M | +6% y/y |
| gaap_income_from_continuing_operations · Q3-2025 | $308M | -32% y/y |
| gaap_eps_from_continuing_operations · Q3-2025 | $0.70 | -34% y/y |
| adjusted_eps · Q3-2025 | $1.09 | 0% y/y |
| cash_from_operating_activities_continuing_ops · Q3-2025 | $591M | -11% y/y |
| transaction_adjusted_free_cash_flow · Q3-2025 | $576M | 0% y/y |
| industrialsco_net_sales · IndustrialsCo · Q3-2025 | $1.80B | +5% y/y |
| industrialsco_operating_ebitda · IndustrialsCo · Q3-2025 | $465M | +4% y/y |
| share_repurchase_authorization · Q4-2025 | $2.00B | |
| accelerated_share_repurchase · Q4-2025 | $500M |
Guidance
FY 2025 operating EBITDA guidance raised to $1.6B
DuPont raised FY 2025 operating EBITDA guidance for new DuPont to $1.6B, citing strong Q3 performance and operational improvements.
Risks flagged
GAAP income from continuing operations declined 32% YoY due to higher separation transaction costs and absence of prior year gains.
“GAAP Income from continuing operations of $308 million, down 32%” · word for word
6 Nov 202510-QDuPont reported strong Q3 2025 results with 7% sales growth, driven by AI-related demand in Electronics, and completed the Electronics Separation on November 1, 2025, with significant capital restructuring.open
Figures in the filing · each found in the filing text
| Net sales · Q3-2025 | $3.07B | +7% y/y |
| Operating EBITDA - IndustrialsCo · IndustrialsCo · Q3-2025 | $465M | +5% y/y |
| Operating EBITDA - ElectronicsCo · ElectronicsCo · Q3-2025 | $403M | +6% y/y |
| Total debt · Q3-2025 | $8.90B | |
| Operating cash flow · 9M-2025 | $1.26B | -17% y/y |
Risks flagged
Electronics Separation execution risk
“The separation involves significant restructuring, financing, and operational changes. The Company recorded $383 million in acquisition, integration and separation costs for 9M 2025.”
Debt refinancing risk
“Total debt increased to $8.9B due to Qnity Notes. Post-separation capital structure involves $4.0B debt repayment and $156M refinancing expenses.”
Macroeconomic uncertainty
“Forward-looking statements reference ongoing supply chain disruptions, inflation, higher interest rates, and trade policy uncertainties.”
3 Nov 20258-K · 1.01, 2.01, 5.02, 7.01, 8.01Qnity shares distributed 209,000,000open
Figures in the filing · each found in the filing text
| Qnity shares distributed · 2025-11-01 | 209,000,000 |
Risks flagged
Separation execution and tax treatment risks
“Ability to realize intended benefits; achievement of intended tax treatment; potential disputes or litigation.”
PFAS legacy liabilities
“Contractual allocation to Qnity of certain legacy liabilities including PFAS; ongoing litigation.”
Aramids divestiture uncertainty
“Ability to timely effect sale of aramids business to TJC LP.”
DuPont de Nemours, Inc. — questions
- What did DuPont de Nemours, Inc. file recently?
- 18 SEC filings in the last 12 months. Latest: 8-K on 2026-09-10 — DuPont, Chemours and Corteva entered into a $455M settlement with North Carolina over PFAS contamination from Fayetteville Works facility. DuPont recorded a $125M probable loss in Q2 2026. Settlement resolves all claims related to PFAS emis
Every figure on this page comes from DuPont de Nemours, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.